AbbVie
ABBV
$167.80
Share price
-1.03%
Change (1 day)
2.27%
Change (1 year)
Categories
The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol “ABBV”.
EPS for AbbVie (ABBV)
EPS in 2023 (TTM): $3.68
According to AbbVie's latest financial reports the company's current EPS (TTM) is $3.68. In 2022 the company made an earnings per share (EPS) of $6.66 an increase over its 2021 EPS that were of $6.49.
EPS history for AbbVie from 2011 to 2023
Annual EPS
| Year | EPS | Change |
|---|---|---|
| 2023 (TTM) | $3.68 | -44.72% |
| 2022 | $6.66 | 2.63% |
| 2021 | $6.49 | 125.21% |
| 2020 | $2.88 | -45.69% |
| 2019 | $5.30 | 48.35% |
| 2018 | $3.58 | 7.6% |
| 2017 | $3.32 | -9.3% |
| 2016 | $3.66 | 15.48% |
| 2015 | $3.17 | 185.53% |
| 2014 | $1.11 | -57.11% |
| 2013 | $2.59 | -21.69% |
| 2012 | $3.31 | 55.73% |
| 2011 | $2.12 |
EPS for similar companies or competitors
| Company | EPS | EPS differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $1.86 | -49.47% | 🇺🇸 USA |
 Eli Lilly LLY | $5.43 | 47.51% | 🇺🇸 USA |
 Amgen AMGN | $14.15 | 284.44% | 🇺🇸 USA |
 Biogen BIIB | $18.46 | 401.54% | 🇺🇸 USA |
 Gilead Sciences GILD | $4.39 | 19.27% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $3.97 | 7.86% | 🇺🇸 USA |
 AstraZeneca AZN | $1.98 | -46.07% | 🇬🇧 UK |
 GlaxoSmithKline GSK | $3.50 | -4.89% | 🇬🇧 UK |
 Neurocrine Biosciences
NBIX | $1.96 | -46.75% | 🇺🇸 USA |